Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MYOS RENS Technology Inc. (NASDAQ: MYOS).

Full DD Report for MYOS

You must become a subscriber to view this report.


Recent News from (NASDAQ: MYOS)

MYOS RENS Technology Announces The Date For The Release Of Third Quarter 2018 Results, Conference Call And Webcast
CEDAR KNOLLS, N.J. , Nov. 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS ), a biotherapeutics and bionutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build lea...
Source: PR Newswire
Date: November, 06 2018 17:26

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-111.801.68011.991.4822,513,037
2018-12-101.101.09631.181.0712,066
2018-12-071.10421.12661.22011.097,782
2018-12-061.161.08121.291.0714148,859
2018-12-051.151.121.151.045,963

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-113,010,7204,988,60460.3520Short
2018-12-104,1816,68162.5805Short
2018-12-071001,8865.3022Cover
2018-12-0611,05325,00644.2014Short
2018-11-304021,50226.7643Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MYOS.


About MYOS RENS Technology Inc. (NASDAQ: MYOS)

Logo for MYOS RENS Technology Inc. (NASDAQ: MYOS)

Nutritional Supplements

 

Contact Information

 

 

Current Management

  • Peter Levy / COO, President
  • Joseph C. DosSantos / CFO
  • Carlon Colker / EVP
  • Carl DeFreitas / Vice President, Corporate Controller
  • Robert C. Ashton, Jr / Chief Med. Officer
  • Buzz Aldrin /
  • Louis Aronne /
  • Peter H. Diamandis /
  • Robert Hariri /

Current Share Structure

  • Market Cap: $7,930,465 - 03/21/2018
  • Issue and Outstanding: 6,344,372 - 11/09/2017

 


Recent Filings from (NASDAQ: MYOS)

Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: May, 10 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: May, 07 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: May, 07 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 02 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 02 2018

 

 


Daily Technical Chart for (NASDAQ: MYOS)

Daily Technical Chart for (NASDAQ: MYOS)


Stay tuned for daily updates and more on (NASDAQ: MYOS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MYOS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MYOS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MYOS and does not buy, sell, or trade any shares of MYOS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/